Chemokine-like receptor 1 (CMKLR1) is a G protein-coupled receptor for chemerin and resolvin E1 that plays a key role in the recruitment and activation of macrophages, natural killer cells and plasmacytoid dendritic cells in inflammatory diseases.
Exegenesis Bio (Hangzhou Exegenesis Biotechnology Co. Ltd.) has received FDA clearance of its IND application for EXG-102-031, a recombinant adeno-associated virus (rAAV)-based gene therapy that is being studied for the treatment of neovascular age-related macular degeneration (AMD).
Researchers from National Cheng Kung University and Taipei Medical University reported the discovery and biological evaluation of novel activating transcription factor 3 (ATF3) inducers as potential candidates for the management of metabolic syndrome.
A noninvasive method for administering monoclonal antibodies reliably and reproducibly to central nervous system (CNS) targets remains a significant unmet need. Researchers in Switzerland have reported making headway in bypassing the blood-brain barrier through the intranasal delivery of full-length antibodies in rodent models. They show this delivery route leads to rapid transfer of significant amounts of a mouse antibody targeted against Nogo-A, a membrane protein that inhibits growth of neurites in the brain and spinal cord.
In animal models, the experimental compound IkT-148009, an inhibitor of Abelson’s tyrosine kinase (c-Abl), prevented the accumulation of the misfolded protein α-synuclein, which is associated with Parkinson’s disease (PD). Treatment with the inhibitor prevented neurodegeneration.
Nanchang Helioeast Technology Co. Ltd. has patented oxa-spirocyclic compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors and reported to be useful for the treatment of acute myeloid leukemia.
Medshine Discovery Inc. has synthesized nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease and systemic lupus erythematosus.
Hangzhou Innogate Pharma Co. Ltd. has identified kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer and viral infections.
Coherent Biopharma Ltd. has divulged peptide-drug conjugates comprising cytotoxic drug covalently linked to folate receptor α (FOLR1; FR- α)-targeting moiety through linker reported to be useful for the treatment of cancer and metabolic, immunological and neurological disorders.
Jazz Pharmaceuticals plc has patented sulfonamides acting as orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
RSS
